J

    Jasper Therapeutics Inc (JSPR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.71
    +0.01 (+1.67%)

    Market Cap: $23.28M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    -1.64%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.56
    Range$-0.56 - $-0.56
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.56+0.0%
    60d ago$-0.56+0.0%
    30d ago$-0.56+0.0%
    7d ago$-0.56+0.0%
    Current$-0.56
    Revenue Consensus
    $2M
    Range$0 - $12M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.87
    Range$-0.87 - $-0.87
    1 analysts
    Revenue Consensus
    $0
    Range$-2400000 - $10M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.87---
    Sep 26EST
    		-$-0.56---
    Jun 26
    		$-0.24$-0.37+35.14%Beat+86.2%
    Mar 26
    		$-0.38$-0.54+29.63%Beat+73.0%
    Dec 25
    		$-0.54$-0.82+33.82%Beat+66.6%
    Sep 25
    		$-1.13$-1.21+6.61%Beat+8.9%
    Jun 25
    		$-1.74$-1.33-30.83%Miss-79.4%
    Mar 25
    		$-1.41$-1.48+4.50%Beat-36.9%
    Dec 24
    		$-1.62$-1.23-31.71%Miss-8.0%
    Sep 24
    		$-1.24$-1.08-14.81%Miss+23.9%
    Jun 24
    		$-0.97$-1.12+13.39%Beat+35.8%
    Mar 24
    		$-1.03$-1.23+16.26%Beat+29.9%
    Dec 23
    		$-1.50$-1.57+4.46%Beat-316.7%
    Sep 23
    		$-1.63$-1.50-8.67%Miss+49.1%
    Jun 23
    		$-1.51$-1.47-2.72%Miss+38.4%
    Mar 23
    		$-1.47$-1.50+2.00%Beat+58.5%
    Dec 22
    		$-0.36$-0.36+0.00%Beat+54.4%
    Sep 22
    		$-3.20$-3.70+13.51%Beat-19.9%
    Jun 22
    		$-2.45$-3.60+31.94%Beat-87.0%
    Mar 22
    		$-3.54$-3.40-4.12%Miss-904.5%
    Dec 21
    		$-0.79$-0.34-132.35%Miss-7800.0%
    Sep 21
    		$-2.67$-2.70+1.11%Beat-13250.0%
    Jun 21
    		$-1.31N/AN/ABeat-6450.0%
    Mar 21
    		$0.44N/AN/ABeat+300.0%
    Dec 20
    		$-0.01N/AN/ABeat-
    Sep 20
    		$-0.02N/AN/ABeat-19900.0%
    Jun 20
    		$-0.02N/AN/ABeat-
    Mar 20
    		$0.11N/AN/ABeat-
    Dec 19
    		$0.00$0.00N/ABeat-
    Sep 19
    		$-0.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.31EV/EBITDA-3.42x
    Price/FCF-0.34xFCF Yield-295.53%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-255.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.47xQuick Ratio1.47x
    Trading Statistics
    Beta3.03Avg Volume716.29K
    52-Week High$2.8752-Week Low$0.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.72
    SMA 20$0.74
    SMA 50$0.65
    SMA 200$1.10
    EMA 10$0.72
    EMA 20$0.72
    EMA 50$0.71
    EMA 200$1.27

    MACD

    Line: 0.01Signal: 0.02Hist: -0.01

    ADX

    ADX: 29.7+DI: 20.2-DI: 13.1

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down16.0
    PSAR$0.94

    Bollinger Bands

    Upper Band$0.88
    Lower Band$0.60
    %B Position3744%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    49.6

    Momentum Oscillators

    Stoch %K15.1
    Stoch %D16.9
    Williams %R-80.3
    ROC (10d)-15.5%
    Momentum-0.13
    CCI (20d)-46.5
    MFI (14d)31.2

    Volatility Measures

    ATR (14d)$0.09(12.8%)
    StdDev (20d)0.07
    Hist Vol107.4%(High)

    Volume Flow

    VWAP$0.70
    OBV-40.6M
    AD Line-49.1M
    CMF (20d)-0.100

    Volume Metrics

    Avg Vol (20d)736.0K
    Vol Ratio0.5x
    VWMA (20d)$0.75

    Pivot Points

    R3$0.77
    R2$0.74
    R1$0.72
    Pivot Point$0.69
    S1$0.67
    S2$0.64
    S3$0.62

    Advanced Oscillators

    TSI3.08
    Ultimate Osc55.5
    KST193.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.17M$0$0$0$2.05M$0
    Cost of Revenue$0$0$290,000$0$0$0$587,000$0$0$0$82,000$0
    Gross Profit$0$0$-290,000$0$0$0$587,000$0$0$0$-82,000$0
    Operating Expenses$9.21M$10.95M$15.84M$19.17M$27.08M$21.80M$25.29M$19.89M$15.99M$15.07M$17.73M$19.36M
    R&D$5.13M$5.81M$11.36M$14.39M$21.20M$16.16M$19.77M$14.46M$11.30M$10.30M$13.84M$14.85M
    SG&A$4.07M$5.14M$4.48M$4.78M$5.88M$5.64M$5.51M$5.43M$4.70M$4.77M$3.89M$4.51M
    Operating Income$-9,207,000$-10,952,000$-15,839,000$-19,166,000$-27,076,000$-21,802,000$-25,285,000$-19,889,000$-15,993,000$-15,072,000$-17,725,000$-19,362,000
    Interest Income$82,000$164,000$338,000$342,000$437,000$624,000$938,000$1.28M$1.45M$1.39M$1.23M$1.43M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,760,000$-1,174,000$-9,101,000$-18,736,000$-26,723,000$-21,241,000$-24,321,000$-18,637,000$-14,583,000$-13,728,000$-16,581,000$-17,544,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,760,000$-1,174,000$-9,101,000$-18,736,000$-26,723,000$-21,241,000$-24,321,000$-18,637,000$-14,583,000$-13,728,000$-16,581,000$-17,544,000
    EBITDA$-2,821,000$-1,317,000$-9,149,000$-18,849,000$-26,902,000$-21,586,000$-25,014,000$-19,380,000$-15,734,000$-14,826,000$-17,532,000$-18,701,000
    EBIT$-2,842,000$-1,338,000$-9,439,000$-19,078,000$-27,160,000$-21,865,000$-25,259,000$-19,921,000$-16,033,000$-15,114,000$-17,815,000$-18,977,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JSPR

    News

    Jasper Therapeutics (NASDAQ: JSPR) eyes reverse split after Nasdaq price warning

    Jasper Therapeutics (NASDAQ: JSPR) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-15 and 1-for-35 due to a Nasdaq price warning. The company also proposes to increase authorized common shares to 675,000,000 to facilitate the conversion of preferred shares from its acquisition of Kira Pharmaceuticals. Stockholders will vote on these proposals at a virtual special meeting on September 30, 2026.

    Stock Titan•8/24/26•
    Somewhat-Bearish

    Velan group shifts to passive stake in Jasper (NASDAQ: JSPR)

    The Velan group, including Velan Capital Investment Management LP, has filed a Schedule 13G indicating a shift to a passive investment stake of approximately 9.9% in Jasper Therapeutics, Inc. (NASDAQ: JSPR). This filing signifies that the group no longer holds Jasper securities with the purpose of influencing control, transitioning from a previous Schedule 13D filing. The beneficial ownership includes shares underlying warrants, with calculations subject to a 9.99% beneficial ownership blocker.

    Stock Titan•8/17/26•
    Neutral

    Jasper Therapeutics beats earnings expectations but stock falls 4%

    Jasper Therapeutics Inc. reported better-than-expected second-quarter fiscal 2026 results, with an adjusted loss per share of $0.10 against an estimated loss of $0.28. Despite this beat, the company's stock fell 4.24% in pre-market trading. The company also highlighted its recent acquisition of Kira Pharmaceuticals and a $132 million financing round, which is expected to fund operations through the second half of 2028.

    Investing.com•8/17/26•
    Somewhat-Bearish

    Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com

    Jasper Therapeutics Inc. reported an adjusted loss per share of $0.10 for Q2 fiscal 2026, beating analyst expectations of a $0.28 loss. Despite this, the company's stock fell 4.24% in pre-market trading. The company recently acquired Kira Pharmaceuticals and closed a $132 million financing round, which they believe will fund operations through the second half of 2028 as they advance three clinical stage assets.

    Investing.com South Africa•8/17/26•
    Neutral

    Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss

    Jasper Therapeutics (JSPR) announced a net loss of $2.8 million for the second quarter ended June 30, 2026. The company recently acquired Kira Pharmaceuticals, raising approximately $132 million, and anticipates releasing interim data and making regulatory filings for its expanded pipeline assets in late 2026 and early 2027. Hedge fund activity shows mixed sentiment, with some institutions increasing their positions while others decreased theirs.

    Quiver Quantitative•8/14/26•
    Somewhat-Bearish

    Frequently Asked Questions About JSPR

    Does JSPR pay dividends?
    Jasper Therapeutics Inc (JSPR) does not currently pay a regular dividend.
    What is JSPR's market cap?
    Jasper Therapeutics Inc (JSPR) has a market capitalization of $23.28M with a current stock price of $0.71.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In